share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5：募资说明书
美股sec公告 ·  05/02 08:18
Moomoo AI 已提取核心信息
Allarity Therapeutics Inc. has filed a prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $4,500,000 to $7,250,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $4,265,000 of its common stock within the last 12 months and is now eligible to sell an additional $2,991,735. The prospectus supplement is part of a registration statement filed on November 29, 2023, and is qualified by the prior prospectus dated March 19, 2024. The company's public float was valued at approximately $21,770,204, with a share price of $8.44 as of March 6, 2024. Allarity Therapeutics cautions that investing in its common stock involves a high degree of risk, as detailed in the 'Risk Factors' section of the prospectus supplement.
Allarity Therapeutics Inc. has filed a prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $4,500,000 to $7,250,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $4,265,000 of its common stock within the last 12 months and is now eligible to sell an additional $2,991,735. The prospectus supplement is part of a registration statement filed on November 29, 2023, and is qualified by the prior prospectus dated March 19, 2024. The company's public float was valued at approximately $21,770,204, with a share price of $8.44 as of March 6, 2024. Allarity Therapeutics cautions that investing in its common stock involves a high degree of risk, as detailed in the 'Risk Factors' section of the prospectus supplement.
Allarity Therapeutics Inc.已于2024年5月2日提交了招股说明书补充文件，将其普通股的最高总发行价从450万美元提高到725万美元。该修正案符合与Ascendiant Capital Markets, LLC签订的市场发行销售协议。在过去的12个月中，该公司已经出售了426.5万美元的普通股，现在有资格再出售2,991,735美元。招股说明书补充文件是2023年11月29日提交的注册声明的一部分，并受2024年3月19日的先前招股说明书的限制。截至2024年3月6日，该公司的公众持股量约为21,770,204美元，股价为8.44美元。Allarity Therapeutics警告说，投资其普通股涉及高度的风险，正如招股说明书补充文件的 “风险因素” 部分所详述的那样。
Allarity Therapeutics Inc.已于2024年5月2日提交了招股说明书补充文件，将其普通股的最高总发行价从450万美元提高到725万美元。该修正案符合与Ascendiant Capital Markets, LLC签订的市场发行销售协议。在过去的12个月中，该公司已经出售了426.5万美元的普通股，现在有资格再出售2,991,735美元。招股说明书补充文件是2023年11月29日提交的注册声明的一部分，并受2024年3月19日的先前招股说明书的限制。截至2024年3月6日，该公司的公众持股量约为21,770,204美元，股价为8.44美元。Allarity Therapeutics警告说，投资其普通股涉及高度的风险，正如招股说明书补充文件的 “风险因素” 部分所详述的那样。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息